Division of Pediatric Gastroenterology and Nutrition, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Shanghai Institute for Pediatric Research, Shanghai, China.
J Nutr. 2022 Feb 8;152(2):377-385. doi: 10.1093/jn/nxab380.
Parenteral nutrition-associated liver disease (PNALD) refers to a spectrum of conditions that can develop cholestasis, steatosis, fibrosis, and cirrhosis in the setting of parenteral nutrition (PN) use. Patient risk factors include short bowel syndrome, bacterial overgrowth and translocation, disturbance of hepatobiliary circulation, and lack of enteral feeding. A growing body of evidence suggests an intricate linkage between the gut microbiota and the pathogenesis of PNALD. In this review, we highlight current knowledge on the taxonomic and functional changes in the gut microbiota that might serve as noninvasive biomarkers. We also discuss the function of microbial metabolites and associated signaling pathways in the pathogenesis of PNALD. By providing the perspectives of microbiota-host interactions in PNALD for basic and translational research and summarizing current limitations of microbiota-based approaches, this review paves the path for developing novel and precise microbiota-based therapies in PNALD.
肠外营养相关肝病(PNALD)是指在肠外营养(PN)使用的情况下,可能会出现胆汁淤积、脂肪变性、纤维化和肝硬化的一系列病症。患者的风险因素包括短肠综合征、细菌过度生长和易位、肝胆循环紊乱以及缺乏肠内喂养。越来越多的证据表明肠道微生物群与 PNALD 的发病机制之间存在复杂的联系。在这篇综述中,我们强调了肠道微生物群在分类和功能上的变化,这些变化可能作为非侵入性生物标志物。我们还讨论了微生物代谢物及其相关信号通路在 PNALD 发病机制中的作用。通过为基础和转化研究提供 PNALD 中微生物群-宿主相互作用的观点,并总结目前基于微生物群的方法的局限性,这篇综述为开发新型、精准的 PNALD 基于微生物群的治疗方法铺平了道路。